Access cutting-edge peripheral t-cell lymphoma treatment through this clinical trial at a research site in Stanford. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Stanford location
Preparing your pre-screening questions…
Access peripheral t-cell lymphoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related peripheral t-cell lymphoma treatment provided free
Check if you qualify for this peripheral t-cell lymphoma clinical trial in Stanford, CA
No-Cost Study Care
Local to Stanford
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to verify whether this prospective collection of data would allow achieving a more accurate information on T-cell lymphomas. The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population as well as molecular markers and to explore the prognostic or predictive implications of them in PTCL. The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population.
Sponsor: Associazione Angela Serra per la ricerca sul cancro
Yes, this clinical trial (NCT03964480) has an active research site in Stanford, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for peripheral t-cell lymphoma treatment options in Stanford, CA, this clinical trial (NCT03964480) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Stanford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced peripheral t-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all peripheral t-cell lymphoma clinical trials near you to find additional studies recruiting in your area.
See all lymphoma clinical trials recruiting in Stanford — not just this study.
Browse Lymphoma Trials in Stanford →